Xenetic Biosciences, Inc. (NASDAQ:XBIO) Files An 8-K Other EventsItem 8.01 Other Events
On October 2, 2017, Xenetic Biosciences, Inc. (the “Company”) provided an update on its 2017 Annual Meeting of Stockholders (“Annual Meeting”). The Annual Meeting scheduled for Thursday, October 5, 2017 will be rescheduled to a later date in 2017. Updated materials and date for the rescheduled meeting are currently being considered by the Company’s Board of Directors. Stockholders will receive new proxy materials and vote on the updated proposals to be set forth in the Company's definitive proxy statement on Schedule 14A, which will be amended or supplemented to include the updated proposals. Such amendment or supplement to the proxy statement will be filed with the Securities and Exchange Commission and mailed to stockholders as soon as reasonably practicable. A new record date for the Annual Meeting has yet to be approved but will be included in the updated proxy materials, along with the time and location of the Annual Meeting.
About Xenetic Biosciences, Inc. (NASDAQ:XBIO)
Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications. The Company’s technologies include PolyXen, Virexxa, OncoHist and ImuXen. The Company is focused primarily on developing its lead product candidates, including ErepoXen, Virexxa and OncoHist, and PolyXen technology. The Company’s lead product candidate ErepoXen, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa and OncoHist for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively. It is also developing PSA-FVIII.
